Department of Medicine (Geriatrics), University College Cork, Cork T12 DC4A, Ireland.
Department of Geriatric Medicine, Cork University Hospital, Cork T12 DC4A, Ireland.
Age Ageing. 2021 Feb 26;50(2):465-471. doi: 10.1093/ageing/afaa159.
Screening Tool of Older Persons Prescriptions in Frail adults with limited life expectancy (STOPPFrail) criteria were developed in 2017 to assist physicians with deprescribing decisions in older people approaching end-of-life. Updating was required to make the tool more practical, patient-centred and complete.
a thorough literature review was conducted to, first, devise a practical method for identifying older people who are likely to be approaching end-of-life, and second, reassess and update the existing deprescribing criteria. An eight-member panel with a wide-ranging experience in geriatric pharmacotherapy reviewed a new draft of STOPPFrail and were invited to propose new deprescribing criteria. STOPPFrail version 2 was then validated using Delphi consensus methodology.
STOPPFrail version 2 emphasises the importance of shared decision-making in the deprescribing process. A new method for identifying older people who are likely to be approaching end-of-life is included along with 25 deprescribing criteria. Guidance relating to the deprescribing of antihypertensive therapies, anti-anginal medications and vitamin D preparations comprises the new criteria.
STOPPFrail criteria have been updated to assist physicians in efforts to reduce drug-related morbidity and burden for their frailest older patients. Version 2 is based on an up-to-date literature review and consensus validation by a panel of experts.
旨在协助医师在生命预期有限的衰弱老年人中进行减药决策的衰弱老年人预期寿命有限的处方筛选工具(STOPPFrail)标准于 2017 年制定。为使工具更实用、以患者为中心和更完整,需要进行更新。
首先,进行了全面的文献复习,以制定一种实用的方法来识别接近生命终点的老年人,并重新评估和更新现有的减药标准。一个在老年药物治疗方面具有广泛经验的 8 人小组审查了 STOPPFrail 的新草案,并被邀请提出新的减药标准。然后使用 Delphi 共识方法验证了 STOPPFrail 版本 2。
STOPPFrail 版本 2 强调了在减药过程中共同决策的重要性。纳入了一种新的识别接近生命终点的老年人的方法以及 25 条减药标准。新的标准包括与降压治疗、抗心绞痛药物和维生素 D 制剂的减药相关的指南。
更新了 STOPPFrail 标准,以协助医师努力减少最虚弱的老年患者的药物相关发病率和负担。版本 2 基于最新的文献综述和专家组的共识验证。